The heart of insitro’s strategy is the development of novel, cutting edge methods in machine learning and high-throughput biology that address key bottlenecks in the drug development pipeline. To accomplish that, we are putting together a team of life scientists with expertise in cellular and biochemical assays. In this role, you will lead projects focused on identifying and validating intermediate phenotypes of disease processes. In collaboration with the Functional Genomics, Disease Modelling and Process Engineering groups, you will develop liver disease phenotypic assays to enable screening of chemical libraries and genetically modified cells. There will be the opportunity for career development and over time taking on the responsibility of target prosecution and the establishment of validated biomarker assays that can be used for IND applications and/or clinical development programs.
Your primary duties will be to:
You will be joining a biotech startup that has long-term stability due to significant funding, but yet is very much in formation. A lot can change in this early and exciting phase, providing many opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro’s culture, strategic direction, and outcomes. Join us, and help make a difference to patients!
Benefits at insitro
insitro is a drug discovery and development company using machine learning and data generation at scale to transform the way that drugs are discovered and delivered to patients. We rely on human genetic cohorts, human-derived cellular disease models, and high-throughput biology and chemistry to identify coherent patient segments, actionable therapeutic targets, and new or existing chemical matter. The goal is to deliver predictive insights to improve the probability of success and reduce the number of costly dead ends along the R&D journey. The company has established enabling collaborations with Gilead in NASH and Bristol Myers Squibb in ALS and is building a pipeline of wholly owned and partnered medicines leveraging its unique insights on patient biomarkers, targets, and molecules. insitro is located in South San Francisco, CA and has raised over $600M from top tech, biotech, and crossover investors since formation in 2018. For more information on insitro, please visit the company’s website at www.insitro.com.
Your application was submitted successfully.